Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry

Marco Canepa, Ewa Straburzynska-Migaj, Jaroslaw Drozdz, Carla Fernandez-Vivancos, Jose Manuel Garcia Pinilla, Noemi Nyolczas, Pier Luigi Temporelli, Alexandre Mebazaa, Mitja Lainscak, Cécile Laroche, Aldo Pietro Maggioni, Massimo F Piepoli, Andrew J S Coats, Roberto Ferrari, Luigi Tavazzi, ESC-HFA Heart Failure Long-Term Registry Investigators

Research output: Contribution to journalArticle

Abstract

AIMS: To describe the characteristics and assess the 1-year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013.

METHODS AND RESULTS: Overall, 1334/6920 (19.3%) HHF patients and 1322/9409 (14.1%) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co-morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non-COPD than in COPD for angiotensin-converting enzyme inhibitors (+13.7% vs. +7.2%), beta-blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2% for beta-blockers in favour of non-COPD patients (89.8% vs. 81.6%, P < 0.001). At 1-year follow-up, the hazard ratios for COPD in multivariable analysis confirmed its independent association with hospitalizations both in HHF [all-cause: 1.16 (1.04-1.29), for HF: 1.22 (1.05-1.42)] and CHF patients [all-cause: 1.26 (1.13-1.41), for HF: 1.37 (1.17-1.60)]. The association between COPD and all-cause mortality was not confirmed in both groups after adjustments.

CONCLUSIONS: COPD frequently coexists in HHF and CHF, worsens the clinical course of the disease, and significantly impacts its therapeutic management and prognosis. The matter should deserve greater attention from the cardiology community.

Original languageEnglish
JournalEuropean Journal of Heart Failure
DOIs
Publication statusPublished - 2018

Fingerprint

Chronic Obstructive Pulmonary Disease
Registries
Heart Failure
Obstructive Lung Diseases
Therapeutics
Mineralocorticoid Receptor Antagonists
Cardiology
Angiotensin-Converting Enzyme Inhibitors
Hospitalization
Morbidity
Mortality

Keywords

  • Journal Article

Cite this

Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. / Canepa, Marco; Straburzynska-Migaj, Ewa; Drozdz, Jaroslaw; Fernandez-Vivancos, Carla; Pinilla, Jose Manuel Garcia; Nyolczas, Noemi; Temporelli, Pier Luigi; Mebazaa, Alexandre; Lainscak, Mitja; Laroche, Cécile; Maggioni, Aldo Pietro; Piepoli, Massimo F; Coats, Andrew J S; Ferrari, Roberto; Tavazzi, Luigi; ESC-HFA Heart Failure Long-Term Registry Investigators.

In: European Journal of Heart Failure, 2018.

Research output: Contribution to journalArticle

Canepa, M, Straburzynska-Migaj, E, Drozdz, J, Fernandez-Vivancos, C, Pinilla, JMG, Nyolczas, N, Temporelli, PL, Mebazaa, A, Lainscak, M, Laroche, C, Maggioni, AP, Piepoli, MF, Coats, AJS, Ferrari, R, Tavazzi, L & ESC-HFA Heart Failure Long-Term Registry Investigators 2018, 'Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry', European Journal of Heart Failure. https://doi.org/10.1002/ejhf.964
Canepa, Marco ; Straburzynska-Migaj, Ewa ; Drozdz, Jaroslaw ; Fernandez-Vivancos, Carla ; Pinilla, Jose Manuel Garcia ; Nyolczas, Noemi ; Temporelli, Pier Luigi ; Mebazaa, Alexandre ; Lainscak, Mitja ; Laroche, Cécile ; Maggioni, Aldo Pietro ; Piepoli, Massimo F ; Coats, Andrew J S ; Ferrari, Roberto ; Tavazzi, Luigi ; ESC-HFA Heart Failure Long-Term Registry Investigators. / Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. In: European Journal of Heart Failure. 2018.
@article{3d50510a8e87442ebc815b89044d19d6,
title = "Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry",
abstract = "AIMS: To describe the characteristics and assess the 1-year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013.METHODS AND RESULTS: Overall, 1334/6920 (19.3{\%}) HHF patients and 1322/9409 (14.1{\%}) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co-morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non-COPD than in COPD for angiotensin-converting enzyme inhibitors (+13.7{\%} vs. +7.2{\%}), beta-blockers (+20.6{\%} vs. +11.8{\%}) and mineralocorticoid receptor antagonists (+20.9{\%} vs. +17.3{\%}), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2{\%} for beta-blockers in favour of non-COPD patients (89.8{\%} vs. 81.6{\%}, P < 0.001). At 1-year follow-up, the hazard ratios for COPD in multivariable analysis confirmed its independent association with hospitalizations both in HHF [all-cause: 1.16 (1.04-1.29), for HF: 1.22 (1.05-1.42)] and CHF patients [all-cause: 1.26 (1.13-1.41), for HF: 1.37 (1.17-1.60)]. The association between COPD and all-cause mortality was not confirmed in both groups after adjustments.CONCLUSIONS: COPD frequently coexists in HHF and CHF, worsens the clinical course of the disease, and significantly impacts its therapeutic management and prognosis. The matter should deserve greater attention from the cardiology community.",
keywords = "Journal Article",
author = "Marco Canepa and Ewa Straburzynska-Migaj and Jaroslaw Drozdz and Carla Fernandez-Vivancos and Pinilla, {Jose Manuel Garcia} and Noemi Nyolczas and Temporelli, {Pier Luigi} and Alexandre Mebazaa and Mitja Lainscak and C{\'e}cile Laroche and Maggioni, {Aldo Pietro} and Piepoli, {Massimo F} and Coats, {Andrew J S} and Roberto Ferrari and Luigi Tavazzi and {ESC-HFA Heart Failure Long-Term Registry Investigators}",
note = "{\circledC} 2017 The Authors. European Journal of Heart Failure {\circledC} 2017 European Society of Cardiology.",
year = "2018",
doi = "10.1002/ejhf.964",
language = "English",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",

}

TY - JOUR

T1 - Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry

AU - Canepa, Marco

AU - Straburzynska-Migaj, Ewa

AU - Drozdz, Jaroslaw

AU - Fernandez-Vivancos, Carla

AU - Pinilla, Jose Manuel Garcia

AU - Nyolczas, Noemi

AU - Temporelli, Pier Luigi

AU - Mebazaa, Alexandre

AU - Lainscak, Mitja

AU - Laroche, Cécile

AU - Maggioni, Aldo Pietro

AU - Piepoli, Massimo F

AU - Coats, Andrew J S

AU - Ferrari, Roberto

AU - Tavazzi, Luigi

AU - ESC-HFA Heart Failure Long-Term Registry Investigators

N1 - © 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.

PY - 2018

Y1 - 2018

N2 - AIMS: To describe the characteristics and assess the 1-year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013.METHODS AND RESULTS: Overall, 1334/6920 (19.3%) HHF patients and 1322/9409 (14.1%) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co-morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non-COPD than in COPD for angiotensin-converting enzyme inhibitors (+13.7% vs. +7.2%), beta-blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2% for beta-blockers in favour of non-COPD patients (89.8% vs. 81.6%, P < 0.001). At 1-year follow-up, the hazard ratios for COPD in multivariable analysis confirmed its independent association with hospitalizations both in HHF [all-cause: 1.16 (1.04-1.29), for HF: 1.22 (1.05-1.42)] and CHF patients [all-cause: 1.26 (1.13-1.41), for HF: 1.37 (1.17-1.60)]. The association between COPD and all-cause mortality was not confirmed in both groups after adjustments.CONCLUSIONS: COPD frequently coexists in HHF and CHF, worsens the clinical course of the disease, and significantly impacts its therapeutic management and prognosis. The matter should deserve greater attention from the cardiology community.

AB - AIMS: To describe the characteristics and assess the 1-year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013.METHODS AND RESULTS: Overall, 1334/6920 (19.3%) HHF patients and 1322/9409 (14.1%) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co-morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non-COPD than in COPD for angiotensin-converting enzyme inhibitors (+13.7% vs. +7.2%), beta-blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2% for beta-blockers in favour of non-COPD patients (89.8% vs. 81.6%, P < 0.001). At 1-year follow-up, the hazard ratios for COPD in multivariable analysis confirmed its independent association with hospitalizations both in HHF [all-cause: 1.16 (1.04-1.29), for HF: 1.22 (1.05-1.42)] and CHF patients [all-cause: 1.26 (1.13-1.41), for HF: 1.37 (1.17-1.60)]. The association between COPD and all-cause mortality was not confirmed in both groups after adjustments.CONCLUSIONS: COPD frequently coexists in HHF and CHF, worsens the clinical course of the disease, and significantly impacts its therapeutic management and prognosis. The matter should deserve greater attention from the cardiology community.

KW - Journal Article

U2 - 10.1002/ejhf.964

DO - 10.1002/ejhf.964

M3 - Article

C2 - 28949063

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

ER -